Literature DB >> 6535346

Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma.

T Saga, S I Said.   

Abstract

VIP, an endogenous neuropeptide normally present in lungs and other organs, relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma in vitro. Pretreatment of these tissues with indomethacin (1 micrograms/ml) markedly enhances the basal tone and the relaxant effect of VIP. The VIP-induced relaxation, especially of pulmonary artery, has a long duration. As a relaxant of human pulmonary arterial strip, VIP is approximately 200 times as potent as prostacyclin, on a molar basis. The results suggest a possible role for VIP as a modulator of airway and pulmonary vascular tone, and as a potential bronchodilator and pulmonary vasodilator in human subjects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6535346

Source DB:  PubMed          Journal:  Trans Assoc Am Physicians        ISSN: 0066-9458


  10 in total

1.  Gene Deletion of VIP Leads to Increased Mortality Associated with Progressive Right Ventricular Hypertrophy.

Authors:  Anthony M Szema; Sayyed A Hamidi
Journal:  J Cardiovasc Dis       Date:  2014-04-01

2.  VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway.

Authors:  H Aizawa; H Inoue; M Shigyo; S Takata; H Koto; K Matsumoto; N Hara
Journal:  Lung       Date:  1994       Impact factor: 2.584

3.  Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.

Authors:  Ventzislav Petkov; Wilhelm Mosgoeller; Rolf Ziesche; Markus Raderer; Leopold Stiebellehner; Karin Vonbank; Georg-Christian Funk; Gerhard Hamilton; Clemens Novotny; Bernhard Burian; Lutz-Henning Block
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

4.  Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics.

Authors:  Ag Mathioudakis; V Chatzimavridou-Grigoriadou; E Evangelopoulou; Ga Mathioudakis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

5.  Peptidase modulation of vasoactive intestinal peptide pulmonary relaxation in tracheal superfused guinea pig lungs.

Authors:  C M Lilly; M A Martins; J M Drazen
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

Review 6.  Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.

Authors:  Dongmei Wu; Dongwon Lee; Yong Kiel Sung
Journal:  Respir Res       Date:  2011-04-11

7.  VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.

Authors:  Sayyed A Hamidi; Richard Z Lin; Anthony M Szema; Sergey Lyubsky; Ya Ping Jiang; Sami I Said
Journal:  Respir Res       Date:  2011-10-26

8.  NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Anthony M Szema; Edward Forsyth; Benjamin Ying; Sayyed A Hamidi; John J Chen; Sonya Hwang; Jonathan C Li; Debra Sabatini Dwyer; Juan M Ramiro-Diaz; Wieslawa Giermakowska; Laura V Gonzalez Bosc
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

Review 9.  Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.

Authors:  Jessica Lu; Sarah J Piper; Peishen Zhao; Laurence J Miller; Denise Wootten; Patrick M Sexton
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

10.  Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.

Authors:  Jun Yin; Liming Wang; Ning Yin; Arata Tabuchi; Hermann Kuppe; Gerhard Wolff; Wolfgang M Kuebler
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.